MedTrace Logo

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

NCT01934335 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-11-01

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to examine whether treatment with vandetanib has an effect on the tumor cells in breast cancer by examining tissue markers.

Conditions

Interventions

DRUG

Vandetanib

OTHER

Placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Ronald Weigel

    lead OTHER

Principal Investigators

  • Ronal Weigel, MD, PhD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2018-12-21
Completion
2018-12-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01934335 on ClinicalTrials.gov